Toremifene (Acapodene®, GTx), an oral selective estrogen receptor modulator (SERM), significantly reduces the risk of prostate cancer development in a high-risk population of men, those with prostatic intraepithelial neoplasia (PIN), according to results from a presentation at the 41st Annual Meeting of the American Society of Clinical Oncology, held in Orlando, FL, May 14 to May 17, 2005.
Go to Previous Page
Go to Next Page